Study registration: *
Publication Glampson B, medRxiv, 2021
Dates: 2020-12-08 to 2021-02-24
Funding: Mixed (Imperial Clinical Analytics Research and Evaluation (iCARE) environment, Whole Systems Integrated Care and used the iCARE & WSIC team and data resources, National Institute for Health Research (NIHR), Imperial Biomedical Research Centre (BRC), National Institute of Health Research (NIHR) Imperial Patient Safety Translational Research Centre, NW London NIHR Applied Research Collaboration.)
Conflict of interest: no COI (The authors have declared no competing interest.)

Methods

Study design:Cohort
Description of participants: Adults (16 years and older) eligible to be offered a COVID-19 in the UK.
Inclusion criteria:
  • All adults over the age of 16
  • Eligible to be offered a COVID-19 vaccine
  • Registered with a GP or with a resident postcode in the North West London catchment area

Exclusion criteria:
  • Individuals that received Moderna vaccines

Follow-up duration (months): 2.56
Vaccines:
  • 1 dose of BNT162b2
  • 1 dose of ChAdOx1-S
Variant description :
Variant name: Alpha
Evidence: Indirect evidence (prevalence of variant in the population: 20 to 95%)
Documents
available

Protocol

NR

Statistical plan

NR

Data-sharing stated: Unclear
Data accessibility: We are unable to extract or publish patient level data from the iCARE and Whole systems integrated care due to data protection restrictions. Any request to access data can be made to Nwlccgs.covid19IG@nhs.ne t referring to the title of this paper.

General comment Concerns around lack of controlling for important potential confounders, possible selection bias and excluding patients who died.